Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 5/20 | 0.39 |
| ▸ | CDK13 | Q14004 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | CCNH | P51946 | 2/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CCNK | O75909 | 2/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463603 | 1.00 | EGFR (0.41) | EGFRLCKBTKCNR2CDK7 | |
| SCHEMBL13563754 | 0.86 | EGFR (0.42) | EGFRLCKBTKCNR2CDK7 | |
| SCHEMBL16900168 | 0.86 | EGFR (0.42) | EGFRLCKBTKCNR2CDK7 | |
| SCHEMBL22388665 | 0.84 | EGFR (0.41) | EGFRLCKBTKCNR2CDK7 | |
| SCHEMBL410297 | 0.78 | CDK13 (0.39) | EGFRLCKBTKCNR2CDK7 | |
| SCHEMBL20206200 | 0.77 | POLB (0.42) | BTKRAB9ANPC1SMN1; SMN2EPHX1 | |
| SCHEMBL16665574 | 0.76 | SMN1; SMN2 (0.46) | EGFRBTKCDK7CDK13SMN1; SMN2 | |
| SCHEMBL27451925 | 0.75 | MEN1 (0.41) | EGFRBTKCDK7CDK13SMN1; SMN2 | |
| SCHEMBL27451922 | 0.75 | MEN1 (0.41) | EGFRBTKCDK7CDK13SMN1; SMN2 | |
| SCHEMBL14079971 | 0.75 | MEN1 (0.41) | EGFRBTKCDK7CDK13SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| US-9556182-B2 | Inhibitors of Bruton's tyrosine kinase | Pharmacylics LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9278100-B2 | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS LLC (US) | 2016-03-08 | — | — | US | disclosed |
| US-9181263-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150307500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-10-29 | — | — | US | disclosed |
| US-20150306106-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-10-29 | — | — | US | disclosed |
| US-20150265618-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-09-24 | — | — | US | disclosed |
| US-9139591-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20120202264-A1 | INHIBITORS OF IL2-INDUCIBLE T-CELL KINASE | PHARMACYCLICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120184013-A1 | Inhibitors of BMX non-receptor tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | BLK, DCK, LTK | EGFR 906/4885LCK 7/4885BTK 14/4885 |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | EGFR 497/4885LCK 8/4885BTK 1/4885 |
| US-20150306106-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20150307500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20150265618-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | EGFR 497/4885LCK 8/4885BTK 1/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 697/4885LCK 23/4885BTK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.